Return on Investment of the COVID-19 Vaccination Campaign in New York City.
Return on Investment of the COVID-19 Vaccination Campaign in New York City.
复制标题
DOI：
10.1001/jamanetworkopen.2022.43127
复制
发表时间：
2022-11-01
影响因子：
13.8
通讯作者：
Galvani, Alison P.
中科院分区：
文献类型：
--
作者：
Sah, Pratha;Vilches, Thomas N.;Moghadas, Seyed M.;Pandey, Abhishek;Gondi, Suhas;Schneider, Eric C.;Singer, Jesse;Chokshi, Dave A.;Galvani, Alison P.
该决策分析模型估计了纽约市全市COVID-19疫苗接种计划的直接和间接成本以及相关收益。COVID-19病例、住院和死亡人数的减少所带来的经济节省是否超过了纽约市对COVID-19疫苗接种计划的投资？在这项对全市范围内的倡议进行的决策分析模型研究中，纽约市疫苗接种运动每投入1美元，估计就能节省10.19美元的成本，因为感染率和死亡率较低，生产力损失较少，并避免了医疗保健的使用。这项研究的结果表明，在纽约市接种COVID-19疫苗与减少严重后果和避免重大经济损失有关。作为疫情的早期中心，纽约市投入巨资开展COVID-19疫苗接种活动，以减轻疾病爆发的负担。了解这一活动的投资回报率（ROI）将有助于了解疫苗接种计划，以遏制未来的COVID-19爆发。通过从社会角度估计有形直接和间接成本，估计纽约市COVID-19疫苗接种活动的投资回报率。该疾病传播决策分析模型针对2020年12月14日至2022年1月31日期间纽约市的COVID-19确诊和可能病例进行了校准。这一模拟模型与同期报告的住院和死亡的观察模式进行了验证。一个基于代理的反事实的情况下，没有接种疫苗的模拟使用校准模型。在有疫苗接种的实际流行轨迹和没有疫苗接种的反事实情景中，估计了卫生保健和死亡的成本。还估计了疫苗接种所实现的节省，这与减少门诊、急诊、紧急医疗服务、住院和重症监护病房入院有关。在计算投资回报率时，考虑了因COVID-19死亡而损失的统计寿命（VSL）价值和因疾病而损失的生产力。在研究期间，疫苗接种运动避免了估计27.96美元的费用，（95%可信区间[CrI]，261.9 - 298.4）亿美元的卫生保健支出和315724（95% CrI，292 143-340 420）潜在寿命损失，避免VSL损失262.7（95% CrI，243.9 - 282.1）亿美元。估计可归因于疫苗接种的净节省为51.77亿美元（95% CrI，48.50 - 558.5美元）。每投资1美元接种疫苗，估计可节省10.19美元（95% CrI，9.39 - 10.87美元）的直接和间接健康成本，而这些成本在没有接种疫苗的情况下会发生。这项建模研究的结果显示，纽约市COVID-19疫苗接种活动与严重后果的减少和避免重大经济损失有关。这一显著的投资回报率支持在持续的大流行期间继续投资于提高疫苗接种率。
This decision analytical model estimates the direct and indirect costs as well as the benefits associated with a citywide COVID-19 vaccination initiative in New York City. Did the economic savings accrued from reductions in COVID-19 cases, hospitalizations, and deaths outweigh the investment in the COVID-19 vaccination program in New York City? In this decision analytical model study of a citywide initiative, every $1 invested in the New York City vaccination campaign yielded an estimated $10.19 in cost savings from lower infection and mortality rates, fewer productivity losses, and averted health care use. Findings of this study suggest that COVID-19 vaccination in New York City was associated with reduction in severe outcomes and avoidance of substantial economic losses. New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 outbreaks. To estimate the ROI of the New York City COVID-19 vaccination campaign by estimating the tangible direct and indirect costs from a societal perspective. This decision analytical model of disease transmission was calibrated to confirmed and probable cases of COVID-19 in New York City between December 14, 2020, and January 31, 2022. This simulation model was validated with observed patterns of reported hospitalizations and deaths during the same period. An agent-based counterfactual scenario without vaccination was simulated using the calibrated model. Costs of health care and deaths were estimated in the actual pandemic trajectory with vaccination and in the counterfactual scenario without vaccination. The savings achieved by vaccination, which were associated with fewer outpatient visits, emergency department visits, emergency medical services, hospitalizations, and intensive care unit admissions, were also estimated. The value of a statistical life (VSL) lost due to COVID-19 death and the productivity loss from illness were accounted for in calculating the ROI. During the study period, the vaccination campaign averted an estimated $27.96 (95% credible interval [CrI], $26.19-$29.84) billion in health care expenditures and 315 724 (95% CrI, 292 143-340 420) potential years of life lost, averting VSL loss of $26.27 (95% CrI, $24.39-$28.21) billion. The estimated net savings attributable to vaccination were $51.77 (95% CrI, $48.50-$55.85) billion. Every $1 invested in vaccination yielded estimated savings of $10.19 (95% CrI, $9.39-$10.87) in direct and indirect costs of health outcomes that would have been incurred without vaccination. Results of this modeling study showed an association of the New York City COVID-19 vaccination campaign with reduction in severe outcomes and avoidance of substantial economic losses. This significant ROI supports continued investment in improving vaccine uptake during the ongoing pandemic.
登录
查看更多内容
影响因子：
33.9
作者：
Shay, David K.;Gee, Julianne;Su, John R.;Myers, Tanya R.;Marquez, Paige;Liu, Ruiling;Zhang, Bicheng;Licata, Charles;Clark, Thomas A.;Shimabukuro, Tom T.
通讯作者：
Shimabukuro, Tom T.
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1093/cid/ciab079
发表时间：
2021-12-16
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Moghadas SM;Vilches TN;Zhang K;Wells CR;Shoukat A;Singer BH;Meyers LA;Neuzil KM;Langley JM;Fitzpatrick MC;Galvani AP
通讯作者：
Galvani AP
影响因子：
3.2
作者：
Haacker, Markus;Hallett, Timothy B.;Atun, Rifat
通讯作者：
Atun, Rifat
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group